Frontal fibrosing alopecia: diagnosis, treatment and hair transplant decisions

Which changes should prompt a medical appointment?

The first change may be a hairline that gradually moves backwards across the forehead or at the temples. The exposed skin can look smoother or paler, with a few isolated hairs left in front of the new border. The pattern is not always even: diffuse thinning or less obvious changes can be mistaken for ordinary ageing.

Thinning eyebrows are another reason to seek advice, even if you have not noticed any movement of the hairline. Eyelashes, sideburns, beard hair in men and some body hair can also be affected. These findings cannot identify the condition on their own, but their combination helps a dermatologist decide what to examine.

Itching, burning or small scales around individual hairs may accompany the changes. However, a comfortable scalp with no obvious redness can still have active disease. Small facial bumps or changes in pigmentation are also worth mentioning, although they do not automatically indicate this type of alopecia.

Arrange an appointment if these changes develop or progress, rather than waiting for extensive hair loss. In the UK, your GP can assess the problem and arrange a dermatology referral where appropriate. Bring older photographs, an approximate timeline and details of treatments you have tried; if you are already under specialist care and notice faster recession or eyebrow loss, contact the team to review your follow-up.

How is the diagnosis established?

The examination covers more than the hairline

The dermatologist examines the hairline, the rest of the scalp and the eyebrows, checking other sites when your symptoms suggest this is needed. They also ask about hairstyles, medical history, medicines and how the changes developed. A photograph sent on its own cannot provide all this information or reliably distinguish current inflammation from established scarring.

Trichoscopy uses a magnifying instrument to examine the scalp and individual hairs. It helps the clinician assess follicular openings, scale and inflammation around the hairs. The multicentre study published by Starace and colleagues in 2022 supports its use alongside a clinical examination, although some presentations still require further investigation.

A biopsy may clarify an uncertain finding

If the appearance is unusual or several diagnoses remain possible, a scalp biopsy may be offered. A small skin sample is taken under local anaesthetic and examined under a microscope for inflammation and fibrosis. Choosing the site matters: sampling only a completely scarred area may reveal less about the process currently affecting nearby follicles.

There is no blood test that establishes frontal fibrosing alopecia on its own. Tests may help investigate another cause of hair loss, an associated condition or the safety of a proposed medicine, depending on the examination and medical history. Each investigation should answer a particular clinical question, rather than assuming that every change in hair growth reflects a hormone problem or nutritional deficiency.

How does this differ from pattern hair loss?

The different types of alopecia affect hair through different mechanisms. In frontal fibrosing alopecia, immune cells contribute to inflammation around the follicle, including a region needed for its continued renewal. Once that structure has been replaced by scar tissue, medication cannot recreate a functioning follicle.

The condition belongs to the scarring alopecias and shares features with lichen planopilaris. It therefore involves more than hairs gradually becoming finer with age. This distinction explains why a delay in diagnosis can reduce the opportunity to protect the remaining hair, even when the visible area of loss still seems small.

Androgenetic alopecia mainly involves progressive miniaturisation of susceptible hairs. It can occur alongside frontal fibrosing alopecia, so treating overall density may leave the inflammatory condition uncontrolled. An improvement in hair coverage over the top of the scalp does not, by itself, show that inflammation at the hairline has resolved.

Alopecia areata and repeated tension from tight hairstyles are other possibilities the clinician may consider. Patches of hair loss, sparse eyebrows or receding temples can have different explanations and need different care. Matching your forehead to an online photograph cannot replace an examination of the scalp and follicles.

Who develops it, and what is known about the causes?

Women after the menopause account for many of the reported cases, but younger women and men can also develop the condition. It affects people with different skin tones, and inflammatory changes may be less obvious on darker skin. Age, sex or the absence of clearly visible redness therefore cannot rule it out.

The exact cause remains uncertain, with genetic susceptibility, immune responses and environmental influences all being investigated. Family clusters occur, but inheritance does not follow a simple, predictable pattern. Its frequency after the menopause does not establish that oestrogen deficiency explains every case or that hormone replacement therapy treats this form of alopecia.

Studies of cosmetics and sunscreens describe associations that do not, on their own, demonstrate cause and effect. They do not justify abandoning sun protection or blaming a particular product without assessment. The international SOFFIA consensus recommends maintaining appropriate protection from the sun; irritation caused by an individual skincare product can be discussed separately with your dermatologist.

Which treatments may protect the remaining hair?

Reducing inflammation in the affected skin

A topical corticosteroid may be prescribed for the affected areas, sometimes alongside another local treatment such as tacrolimus. A dermatologist may also inject corticosteroid into selected parts of the scalp or eyebrows. The choice depends on disease activity, the treatment site and the condition of the skin; prolonged applications or unsuitable injections can cause problems such as skin thinning.

The aim is to reduce symptoms and limit damage to follicles that are still present. Some regrowth may occasionally occur, particularly in eyebrows where viable follicles remain. This possibility is different from regenerating an area in which the follicles have already been lost.

Considering oral medicines individually

Finasteride, dutasteride and hydroxychloroquine are among the options discussed in specialist publications. The SOFFIA consensus identifies them as commonly considered systemic treatments, without proposing the same prescription for everyone. Their use for this condition requires an individual medical decision, often outside their licensed indication, taking account of health history, interactions and potential adverse effects.

Monitoring depends on the medicine chosen: hydroxychloroquine, for example, requires attention to the risk of retinal damage. Tell the prescriber about any plans for pregnancy; finasteride, in particular, must not be used during pregnancy or breastfeeding. Certain tetracyclines and other medicines that modify immune activity may be considered in particular circumstances, after weighing the expected benefit against the risks.

Separating better density from disease control

Minoxidil may improve the density of hair that remains, especially when pattern hair loss is also present. Used on its own, it does not adequately control the inflammation characteristic of frontal fibrosing alopecia. A treatment that makes existing hair look fuller and a treatment that limits further scarring therefore serve different purposes.

Evidence for platelet-rich plasma, lasers, photobiomodulation and so-called regenerative approaches remains insufficient to promise restoration of the hairline. A few favourable reports cannot establish predictable effectiveness, particularly when several treatments were given together. Shampoos and nutritional supplements should not be presented as a way to eliminate this inflammatory disease either.

How can you tell whether the condition is settling?

Follow-up compares measurements of the hairline, photographs taken under similar conditions and trichoscopic findings. The clinician also considers symptoms, scale and other signs of activity. Different lighting or a change of hairstyle can otherwise create a misleading impression that the condition has improved or worsened.

Relief from itching does not establish that the disease has become inactive. Equally, a hairline that appears unchanged in two photographs does not capture the whole assessment. The aim is to combine several observations over time, with appointment intervals adjusted to the rate of change and the treatment being used.

Assessment usually takes several months; the SOFFIA consensus suggests a six-month treatment trial before judging effectiveness, adjusted to the clinical circumstances. Adverse effects or worsening symptoms should still be reported without waiting for that point. Reducing or stopping medication is a decision for the prescriber, as activity can return after a quiet period.

The course varies considerably, and spontaneous stabilisation can occur without a predictable timetable for an individual. Published studies often involve small groups, combinations of medicines and different follow-up periods. These limitations mean a reported response percentage cannot be converted into a personal forecast or a promise of lasting remission.

What can help with everyday life?

A loose hairstyle, hairpiece or wig may make the recession less noticeable while medical follow-up continues. For eyebrows, removable make-up allows you to try a shape without a permanent procedure. Choices depend on comfort, the appearance you prefer and the condition of your skin, with particular attention to irritating products or attachments.

Avoid hairstyles that place sustained tension on an already vulnerable hairline, and choose products your scalp tolerates. These adjustments reduce local strain but do not replace treatment of the inflammation. If you are considering micropigmentation or another procedure that affects the skin, seek advice first when the disease remains active or the area is irritated.

Losing scalp or eyebrow hair can affect self-image and make social situations harder. You can discuss this with your clinician, a counsellor or a support organisation, depending on the help you would find useful. The emotional impact deserves a place in decisions about treatment and camouflage, even when the measured area of hair loss is relatively small.

Could a hair transplant be considered after stabilisation?

Inactivity must be documented over time

The SOFFIA consensus recommends at least twenty-four months of disease inactivity before considering transplantation in selected cases. This is an expert recommendation, not automatic clearance for surgery once that interval has passed. Photographic stability must be considered alongside symptoms and inflammatory signs, together with an examination of the proposed donor area.

Inflammatory scarring alopecia does not behave like an old scar caused by an injury. Our explanation of hair transplantation into scar tissue covers general limitations of the recipient skin, but frontal fibrosing alopecia requires an additional assessment of disease activity. Choosing a different harvesting technique does not make an actively inflamed area suitable for transplantation.

Transplanted follicles remain vulnerable

Newly implanted follicles can subsequently be affected by the inflammatory process, reducing coverage over the following years. Surgery itself may reactivate the condition, and satisfactory early growth cannot establish that grafts will survive indefinitely. Dermatology follow-up and the potential need for continued medication therefore remain relevant well beyond the early postoperative period.

The guide to the hair transplant process explains harvesting, implantation and usual recovery. For this particular diagnosis, decisions about graft numbers and technique come after assessment of the medical risk. Continued observation or cosmetic camouflage may remain preferable, even when someone strongly wishes to reconstruct their hairline.

Preparing for an assessment in Istanbul

If you wish to discuss your suitability for a hair transplant in Istanbul, gather your dermatologist’s report, relevant test results and available follow-up photographs. Include current medicines, any adverse effects and the dates of the most recent changes you have noticed. At Body Expert, this information helps us assess your plans with our partner clinic in Istanbul before arranging a stay.

Where the disease remains active or the diagnosis is uncertain, further dermatological assessment takes priority. Our English-speaking patient coordinator and the twelve-month postoperative follow-up provided for a transplant do not replace long-term monitoring of this condition. An appropriate decision may therefore be to defer surgery, continue using camouflage or decide against an operation.

Sources

Meah, N., Li, J., Wall, D., et al. (2026). Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024. Journal of the European Academy of Dermatology and Venereology, 40(2), 210–223. First published online in 2025. https://doi.org/10.1111/jdv.20833

Starace, M., Cedirian, S., Rapparini, L., Quadrelli, F., Pampaloni, F., Bruni, F., & Piraccini, B. M. (2024). Enhanced insights into frontal fibrosing alopecia: Advancements in pathogenesis understanding and management strategies. Dermatology and Therapy, 14, 1457–1477. https://doi.org/10.1007/s13555-024-01186-0

Starace, M., Orlando, G., Iorizzo, M., et al. (2022). Clinical and dermoscopic approaches to diagnosis of frontal fibrosing alopecia: Results from a multicenter study of the International Dermoscopy Society. Dermatology Practical & Conceptual, 12(1), e2022080. https://doi.org/10.5826/dpc.1201a80

Verma, S., Marak, A., & Paul, D. (2025). Frontal fibrosing alopecia: A comprehensive review with recent updates. Indian Journal of Dermatology, 70(2), 115. https://doi.org/10.4103/ijd.ijd_419_24

Gloucestershire Hospitals NHS Foundation Trust. (2025). Finasteride for women (GHPI1510_02_25). https://www.gloshospitals.nhs.uk/your-visit/patient-information-leaflets/finasteride-for-women/